Context The contribution of [18F]F-fluorocholine (FCH)PET/CT in normocalcemic primary hyperparathyroidism (nPHPT) remains unknown. Objective To evaluate the sensitivity and specificity of FCH-PET/CT in a cohort of osteoporotic nPHPT patients with discordant or negative MIBI scintigraphy and ultrasonography who all underwent parathyroidectomy (PTX). Design Longitudinal retrospective cohort study in patients referred for osteoporosis with mild biological primary hyperparathyroidism. Setting Tertiary referral center with expertise in bone metabolism and surgical management of hyperparathyroidism. Patients Among 109 PHPT patients analyzed, three groups were individualized according to total serum calcium (tCa) and ionized calcium (iCa): 32 hypercalcemic patients (HtCa group), 39 patients with normal tCa and elevated iCa (NtCa group), and 38 patients with both normal tCa and iCa (NiCa). All patients had biochemical follow-up confirming or not the success of PTX. Main outcome measures To evaluate the performance of FCH-PET/CT in terms of sensitivity and specificity, and to compare with first-line imaging procedures in the setting of nPHPT. Results The sensitivity of FCH-PET/CT was 67% in the hypercalcemic, 48% in the NtCa group (p = 0.05 vs HtCa), and 33% in the NiCa group (p = 0.004 vs HtCa). Specificity ranged from 97 to 99%. FCH-PET/CT was positive in 64.3% of patients with negative conventional imaging, with biochemical resolution after PTX in 77.8% of patients. Triple negative imaging was observed in 20 patients, with PHPT resolution in 85% of these patients. Conclusion This study highlights the contribution of [18F]F-fluorocholine PET/CT in a well phenotyped cohort of normocalcemic patients with discordant or negative findings in MIBI scintigraphy and ultrasonography. However, negative imaging in nPHTP does not rule out the possibility of surgical cure by an experienced surgeon.
Although anti-CD38 monoclonal antibodies have improved the prognosis of relapsed/refractory multiple myeloma (RRMM), some patients still experience early relapses with poor outcomes. This present study evaluated the predictive value of FDG PET/CT parameters for RRMM prior to initiating anti-CD38 treatment. We included 38 consecutive RRMM patients who underwent a PET/CT scan treated at our institution at relapse. The median PFS was 12.5 months and the median OS was not reached. 42% of the patients had an initial ISS score of 1, 37% of 2, and 21% of 3. The presence of >3 focal lesions (FLs, n = 19) and the ISS score were associated with inferior PFS (p = 0.0036 and p = 0.0026) and OS (p = 0.025 and p = 0.0098). Patients with >3 FLs had a higher initial ISS score (p = 0.028). In multivariable analysis, the ISS score and >3 FLs were independent prognostic factors for PFS (p = 0.010 and p = 0.025 respectively), and combined they individualized a high-risk group with a median PFS and OS of 3.1 months and 8.5 months respectively vs. not reached for the other patients. The presence of >3 FLs on PET was predictive of survival outcomes in patients with RRMM treated using CD38 targeted therapy. Combined with the initial ISS, an ultra-high-risk RRMM population can thus be identified.
20 November 2020 in Journal of the Endocrine Society
A 56-year-old woman was investigated for a multinodular thyroid goiter. A neck ultrasound identified, in addition to the goiter, a highly vascularized hypoechoi